Credt: Allergan Aesthetics (AbbVie)

Ab­b­Vie teams up with Shut­ter­stock to re­de­fine beau­ty in lat­est aes­thet­ics cam­paign

Ab­b­Vie is set­ting out to change beau­ty stan­dards in aes­thet­ics mar­ket­ing — and to do so, it’s team­ing up with Shut­ter­stock.

The phar­ma gi­ant’s Al­ler­gan Aes­thet­ics unit an­nounced the new part­ner­ship last week as part of its Dri­ving Racial Eq­ui­ty in Aes­thet­ic Med­i­cine, or DREAM Ini­tia­tive, co-found­ed by Skin­bet­ter Sci­ence. In ad­di­tion to pub­lish­ing a new re­port on in­clu­siv­i­ty in beau­ty mar­ket­ing, ti­tled “Forces of Beau­ty,” Ab­b­Vie will launch an ac­com­pa­ny­ing video se­ries pro­duced by Shut­ter­stock Stu­dios.

The videos will spot­light four women and their thoughts on var­i­ous top­ics cov­ered in the re­port, in­clud­ing ap­pro­pri­a­tion, a his­to­ry of beau­ty stan­dards and defin­ing beau­ty. Shut­ter­stock is al­so un­veil­ing a roy­al­ty-free gallery, rep­re­sen­ta­tive of “every gen­der, eth­nic­i­ty, cul­ture, age, and body type.”

“Most of the vi­su­als used in ad­ver­tis­ing and brand­ing do not re­flect the di­ver­si­ty we see around us every day, and an on­line search of im­agery re­veals just how un­der­rep­re­sent­ed many groups are in this space,” Aiden Darné, VP and glob­al head of Shut­ter­stock Stu­dios, said in a news re­lease.

On­ly 31% of women agree that to­day’s beau­ty stan­dards are achiev­able, ac­cord­ing to the DREAM project’s sur­vey of around 4,000 women be­tween the ages of 21 to 65. And one in four Black, Lati­na and mul­tira­cial women deemed so­ci­ety’s beau­ty stan­dards as racist.

“I see cul­tur­al ap­pro­pri­a­tion now more than ever. Black women don’t get ac­knowl­edged for beau­ty like oth­er races and cul­tures do. I feel like we’re robbed,” a woman named Kiyah, who’s al­so fea­tured in a video, said in the re­port.

Ac­cord­ing to the re­port, 38% of women sur­veyed agreed that the biggest change they’d like to see is “re­al women in beau­ty and ad­ver­tis­ing.”

“A good rea­son to seek aes­thet­ic treat­ment is be­cause you want to. Not that you feel pres­sured by so­ci­ety’s views of beau­ty,” Si­mone Hopes, a physi­cian as­sis­tant and DREAM am­bas­sador, said in the re­port.

The re­port was pub­lished less than two weeks af­ter Ab­b­Vie un­veiled its lat­est “See Your­self” Botox Cos­met­ic cam­paign, fea­tur­ing 25 re­al pa­tients who tell their sto­ries be­fore and af­ter Botox treat­ment in short video clips. The mar­ket­ing push comes as Botox gains a longer-last­ing com­peti­tor, Re­vance’s Daxxi­fy, which was ap­proved ear­li­er this month. While peo­ple us­ing Botox may need to re­turn for in­jec­tions every three to four months, Daxxi­fy po­ten­tial­ly re­quires just two in­jec­tions per year.

Botox Cos­met­ic earned Ab­b­Vie $695 mil­lion last quar­ter alone, not ac­count­ing for an­oth­er $678 mil­lion in ther­a­peu­tic set­tings.

“Our re­search pro­vides aes­thet­ics prac­ti­tion­ers, me­dia, and in­dus­try lead­ers in­sights to bet­ter un­der­stand the dy­nam­ic be­tween beau­ty and racial iden­ti­ty for women with­in the Unit­ed States. Let’s make the world of aes­thet­ics more in­clu­sive and bet­ter serve all pa­tients,” the DREAM cam­paign web­site states.

This isn’t Shut­ter­stock’s first Big Phar­ma part­ner­ship. Back in 2020, the com­pa­ny paired with GSK to launch the “HIV in View” cam­paign fea­tur­ing im­ages and videos de­pict­ing “what it re­al­ly means to live with HIV.”

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Emily Leproust, Twist Bioscience CEO

Twist Bio­science’s 'fac­to­ry of the fu­ture' in Ore­gon could de­liv­er with com­pet­i­tive pric­ing, SVB Se­cu­ri­ties says

The synthetic DNA manufacturer Twist Bioscience has given a peek behind the curtain to several analysts into its “factory of the future” as well as insight into the cost structure, workflow and technology at the site.

The 110,000-square-foot manufacturing site in the city of Wilsonville, OR, just south of Portland, which was announced back in 2020, will double Twist’s production capacity and bring around 400 jobs to the area.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting:

Digital render of CPI's Medicines Manufacturing Innovation Centre in Glasgow, Scotland (Image: uk-cpi.com)

CPI opens the doors to a new $100M+ man­u­fac­tur­ing fa­cil­i­ty in Scot­land

A manufacturing site that has received interest and investments from large pharma companies and the UK government is opening its doors in Scotland.

The manufacturer CPI (Centre for Process Innovation) has opened a new £88 million ($105 million) “Medicines Manufacturing Innovation Centre” in Glasgow, Scotland, to accelerate the development of manufacturing tech and solve longstanding challenges in medicine development and manufacturing.

Lex­i­con slams FDA over hear­ing de­nial fol­low­ing a CRL for its SGLT2 in­hibitor can­di­date

Lexicon Pharmaceutical is not giving up on its Type I diabetes candidate, despite FDA’s repeated rejections. This week the company laid out is argument again for a hearing on sotagliflozin in response to the FDA’s most recent denial.

The issue goes back to March 2019 when the FDA made very clear to Lexicon and its now departed partner Sanofi that it would not approve their application for a potential Type I diabetes drug because it does not appear to be safe.

Pro­tect­ing its megablock­buster, Janssen chal­lenges Am­gen's Ste­lara biosim­i­lar ahead of planned 2023 launch

Johnson & Johnson unit Janssen on Wednesday sued Amgen over the company’s proposed biosimilar to its megablockbuster Stelara (ustekinumab), after Amgen said it was ready to launch next May or as soon as the FDA signs off on it.

If Amgen carries through with that plan, Janssen told the Delaware district court that the Thousand Oaks, CA-based company will infringe on at least two Janssen patents.